Nicox
en
fr
Toggle Menu
About Us
Visible Science
Leadership Team
Board of Directors
Glaucoma Advisory Board
Partnerships
Portfolio and Disease Areas
Nicox’s innovative portfolio
Disease focus areas
Our portfolio at a glance
Nitric Oxide Donation
Publications
Investors
Stock Information
Financial and Regulatory Information
Shareholder Meetings
Corporate Presentation
Webcasts
Corporate Governance
Investor Contacts
News and Events
Press Releases
Events and Conferences
Videos
Contact Us
Contact Details
Main subsidiaries
Job opportunities
NCX 470, a Nitric Oxide Donating Bimatoprost Compared with Latanoprost – Adaptive Design Period Results from the Phase 3 Mont Blanc Clinical Trial
July 3, 2023
← Back to blog page
Cookies
By continuing to use this website, you agree to our
Cookie Policy
.
Accept
